抗体-药物偶联物在治疗胃癌和胃食管结合部腺癌中的研究进展  

Progress of antibody-drug conjugates in the treatment of gastric cancer and adenocarcinoma of esophageal-gastric junction

作　　者：许倩[1] 李大鹏[1] Xu Qian;Li Dapeng(Department of Oncology,the First Affiliated Hospital of Soochow University,Suzhou 215006,China)

机构地区：[1]苏州大学附属第一医院肿瘤科,苏州215006

出　　处：《肿瘤研究与临床》2024年第7期549-553,共5页Cancer Research and Clinic

摘　　要：胃癌是起源于胃黏膜上皮的恶性肿瘤,是最常见的消化道恶性肿瘤之一,胃癌患者表现出发病率、转移率、病死率高的特点。胃癌在手术、化疗、免疫疗法等多种治疗下,因高度异质性及转移复发率高,部分患者仍出现疾病复发、转移和预后不良。抗体-药物偶联物是一类由单克隆抗体和小分子细胞毒性载荷通过连接子偶联而成的新型高效抗肿瘤药物,其高度靶向性和小分子化疗药物的强大杀伤作用为胃癌的治疗提供了一个新的方案,目前正在多个临床试验中对不同靶点进行评估。文章主要综述了抗体-药物偶联物在胃癌及胃食管结合部腺癌的最新研究进展以及在未来发展中的挑战。Gastric cancer is a malignant tumor originating from the epithelium of the gastric mucosa and it is one of the most common malignant tumors of the digestive tract.Patients with gastric cancer have high incidence,metastasis rate and mortality rate.Despite various treatments such as surgery,chemotherapy and immunotherapy,some patients still show recurrence,metastasis and poor prognosis due to its high heterogeneity,high recurrence rate and metastasis rate.Antibody-drug conjugates,a novel class of highly efficient anti-tumor drugs composed of monoclonal antibodies and small molecule cytotoxic payloads linked by a connector,provide a new treatment method for the treatment of gastric cancer due to the high targeting specificity and potent cytotoxic effects of small molecule chemotherapy drugs.Currently,they are being evaluated in multiple clinical trials targeting different sites.This article mainly reviews the latest research progress of antibody-drug conjugates in gastric cancer and adenocarcinoma of esophageal-gastric junction,as well as the challenges in the future development.

关 键 词：胃肿瘤 食管胃接合处 受体 erbB-2 抗体 单克隆 分子靶向治疗 

分 类 号：R735.2[医药卫生—肿瘤]